MLAB · CIK 0000724004
What Mesa Laboratories, Inc. told the SEC could break it.
Mesa Laboratories' disclosures center on concentration and international exposure across its life-science divisions. No single customer is more than 10% of consolidated revenue, but at the division level its Clinical Genomics business draws about 20% of its revenue from one customer. Geography is a bigger theme: roughly 53% of fiscal 2026 revenue came from outside the U.S. (8% China, 45% mostly Europe), exposing it to currency swings and to U.S.-China trade tensions that pulled down China sales. It also depends on sole or limited suppliers for certain materials, particularly in its Biopharmaceutical Development and Calibration Solutions divisions, and faces tariffs (which it offset with recovery surcharges), export controls that delayed peptide-system shipments, and FDA medical-device regulation.
4 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Clinical Genomics division — a single (unnamed) customer = ~20% of the division's revenue; reliance on a small number of established customersmedium
While no customer was more than 10% of consolidated revenue or receivables in fiscal 2026, certain Mesa businesses have higher customer concentration at the division level: in its Clinical Genomics division a significant portion of revenue comes from a relatively small number of established customers, with a single (undisclosed) customer accounting for approximately 20% of the division's revenue in fiscal 2026, so loss of that customer would materially affect the division's results.
“In our Clinical Genomics division, a significant portion of revenues is generated from ongoing purchases by a relatively small number of established customers, with a single customer accounting for approximately 20% of the division's revenues in fiscal 2026.”
SEC filing →As of 2026
Other disclosures
- international concentration — ~53% of revenue earned outside the U.S. (8% China, 45% other non-U.S. mainly Europe); China-sales declines, trade tensions and FX exposuremedium
About 53% of Mesa's fiscal 2026 revenue was earned outside the United States (8% from China operations and 45% from other non-U.S. countries, primarily Europe), exposing it to political, economic, regulatory and currency risks: U.S.-China trade tensions and macro/regulatory uncertainty drove lower China sales (Clinical Genomics revenue fell 3.6%, but rose 9.2% excluding China), and foreign-currency fluctuations against the U.S. dollar materially affect reported revenue and margins.
“In fiscal year 2026, we generated approximately 8% of our sales from operations in China and 45% of our sales from other non-U.S. countries, primarily in Europe.”
Sole-source dependency
- dependence on sole or limited sources of supply for certain materials, components and services — particularly in the Biopharmaceutical Development and Calibration Solutions divisionsmedium
Although Mesa generally maintains multiple sources of supply, it is dependent on sole or limited sources for certain materials, components and services, particularly in its Biopharmaceutical Development and Calibration Solutions divisions; disruptions, cost increases or quality/timeliness failures at these sole/limited-source suppliers could cause production interruptions, delays and inefficiencies and adversely affect its ability to supply critical products to customers.
“We generally maintain multiple sources of supply, but we are dependent on sole or limited sources for certain items, particularly in our Biopharmaceutical Development and Calibration Solutions divisions.”
SEC filing →As of 2026
Regulatory & policy
- tariffs (margin pressure, tariff-recovery surcharges) and export controls (blocked peptide-system shipments), plus FDA medical-device regulation and IRA drug-pricing pressure on customerslow
Mesa is exposed to trade and product regulation: tariffs pressured Biopharmaceutical Development gross margins (it added tariff-recovery surcharges), and export controls caused shipping delays that prevented certain peptide-systems shipments in the second half of fiscal 2026; several products across its Sterilization & Disinfection Control, Calibration Solutions and Clinical Genomics divisions are FDA-regulated medical devices subject to 510(k) notification and inspections, and healthcare-funding/IRA drug-pricing changes can reduce customers' reimbursement and procedure volumes.
“Revenues were impacted to a lesser extent by shipping delays related to export controls that prevented the shipment of certain peptides systems in the second half of fiscal year 2026.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch